首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.
【24h】

Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.

机译:新型适当取代的4-(1-哌嗪基)香豆素的合成及其对人血小板聚集的体外抑制活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Pursuing our chemical and biological studies in this field, we described the multistep preparation of the new 5-, 6-, or 7-alkoxy and 7-alkoxy-8-methyl substituted 4-(1-piperazinyl)coumarins 5d-v, as well as the in vitro evaluation of their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen or the Ca(2+) ionophore A23187. Compounds 5h-j,p,r-u showed notably high activity towards all the platelet aggregation inducers used, and the most active one, 8-methyl-4-(1-piperazinyl)-7-(3-pyridylmethoxy)coumarin (5t), proved to be a potent in vitro antiplatelet agent.
机译:在该领域的化学和生物学研究中,我们描述了新的5-,6-或7-烷氧基和7-烷氧基-8-甲基取代的4-(1-哌嗪基)香豆素5d-v的多步制备方法,以及它们对ADP,胶原蛋白或Ca(2+)离子载体A23187在富含血小板的血浆中诱导的人血小板聚集的抑制活性的体外评估。化合物5h-j,p,ru对所有使用的血小板聚集诱导剂均具有显着的活性,而活性最高的一种是8-甲基-4-(1-哌嗪基)-7-(3-吡啶甲氧基)香豆素(5t),被证明是有效的体外抗血小板药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号